Dipentum

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1986-2011
02419862011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Patients receiving 5-aminosalicylic acid (5-ASA) require long-term therapy to achieve good outcomes. Persistency (duration of… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2006
2006
BACKGROUND/AIMS In the treatment of ulcerative colitis, 5-aminosalicylic acid is the standard therapy for both acute… (More)
Is this relevant?
1996
1996
BACKGROUND All 5-aminosalicylic acid (5-ASA) preparations are potentially nephrotoxic, but there has been concern that newer… (More)
Is this relevant?
1996
1996
AIM To determine the systemic uptake of 5-aminosalicylic acid (5-ASA) and acetyl-5-ASA (Ac-5-ASA) at steady state during… (More)
Is this relevant?
1996
1996
UNLABELLED Aminosalicylates are used to maintain remission in patients with ulcerative colitis. Since there are potential… (More)
Is this relevant?
1992
1992
Intramucosal 5-aminosalicylic acid (5-ASA) and acetylated 5-ASA (Ac-5-ASA) concentrations were determined in ileocolonic biopsy… (More)
  • table I
  • table II
  • table IV
  • table V
Is this relevant?
1992
1992
Sulphasalazine extends remissions and lessens disease activity during relapses of ulcerative colitis, but it also causes many… (More)
Is this relevant?
1991
1991
Dipentum (olsalazine sodium), a product by Pharmacia, represents the first oral delivery of sulfa-free 5-aminosalicylic acid… (More)
Is this relevant?
1987
1987
Sulfasalazine is a potent inhibitor of superoxide production and granule enzyme release by stimulated neutrophils, and modulation… (More)
Is this relevant?
1986
1986
One hundred sixty patients intolerant of or allergic to sulfasalazine (Salazopyrin, Azulfidine) participated in an open tolerance… (More)
Is this relevant?